title: pH-dependent stability of creatine ethyl ester: relevance to oral absorption.
abstract: Creatine ethyl ester hydrochloride (CEE) was synthesized as a prodrug of creatine (CRT) to improve aqueous solubility, gastrointestinal permeability, and ultimately the pharmacodynamics of CRT. We used high-performance liquid chromatography (HPLC) and proton nuclear magnetic resonance (NMR) to characterize the pH-dependent stability of CEE in aqueous solution and compared the permeability of CEE to CRT and creatinine (CRN) across Caco-2 human epithelial cell monolayers and transdermal permeability across porcine skin. CEE was most stable in a strongly acidic condition (half-life = 570 hours at pH 1.0) where it undergoes ester hydrolysis to CRT and ethanol. At pH ≥ 1.0, CEE cyclizes to CRN with the logarithm of the first order rate constant increasing linearly with pH. Above pH 8.0 (half-life = 23 sec) the rate of degradation was too rapid to be determined. The rate of degradation of CEE in cell culture media and simulated intestinal fluid (SIF) was a function of pH and correlated well with the stability in aqueous buffered solutions. The permeability of CEE across Caco-2 monolayers and porcine skin was significantly greater than that of CRT or CRN. The stability of CEE in acidic media together with its improved permeability suggests that CEE has potential for improved oral absorption compared to CRT.
authors: College of Pharmacy University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.
authors: Brandon T
authors: BT
authors: Gufford
authors: Edward L
authors: EL
authors: Ezell
authors: Dennis H
authors: DH
authors: Robinson
authors: Donald W
authors: DW
authors: Miller
authors: Nicholas J
authors: NJ
authors: Miller
authors: Xiaochen
authors: X
authors: Gu
authors: Jonathan L
authors: JL
authors: Vennerstrom
mesh_terms: D000284:Administration, Oral; D000818:Animals; D018938:Caco-2 Cells; D002626:Chemistry, Pharmaceutical; D003401:Creatine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D004355:Drug Stability; D005744:Gastric Acid; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007413:Intestinal Mucosa / Q000378:metabolism*; D011355:Prodrugs / Q000008:administration & dosage / Q000378:metabolism*; D012867:Skin / Q000378:metabolism*; D013552:Swine
chemical_list: D011355:Prodrugs; D003404:Creatinine; C542315:creatine ethyl ester; D003401:Creatine
references: Int J Sports Med. 2009 Oct;30(10):766-70
references: 19585404
references: Clin Pharmacokinet. 2003;42(6):557-74
references: 12793840
references: Neurourol Urodyn. 2011 Nov;30(8):1633-8
references: 21826715
references: Curr Protoc Toxicol. 2011 Feb;Chapter 20:Unit20.6
references: 21400683
references: J Int Soc Sports Nutr. 2009 Feb 19;6:6
references: 19228401
references: Med Sci Sports Exerc. 2000 Mar;32(3):706-17
references: 10731017
references: Biochem Biophys Res Commun. 2009 Aug 21;386(2):363-7
references: 19524547
references: Neth J Med. 2011 Feb;69(2):79-81
references: 21411845
references: J Sports Sci Med. 2003 Dec 01;2(4):123-32
references: 24688272
references: Life Sci. 1999 Oct 29;65(23):2463-70
references: 10622230
references: J Int Soc Sports Nutr. 2007 Aug 30;4:6
references: 17908288
references: J Clin Pharmacol. 2003 Jan;43(1):29-37
references: 12520625
references: J Diet Suppl. 2010 Sep;7(3):240-52
references: 22432515
references: Neuroscience. 2011 Dec 29;199:386-93
references: 21963865
references: Eur J Appl Physiol Occup Physiol. 1997;76(6):566-7
references: 9404870
references: Biochem Biophys Res Commun. 2009 Oct 16;388(2):252-5
references: 19660433
references: Int Immunopharmacol. 2011 Sep;11(9):1341-7
references: 21575742